Skip to main content
. 2021 Jan 8;40(7):1255–1268. doi: 10.1038/s41388-020-01595-3

Fig. 3. The status of the chrXq27.3 miRNA cluster in a preclinical model and its function in cisplatin sensitivity.

Fig. 3

A Expression of the chrXq27.3 miRNA cluster in several cell lines. miR-25-3p and miR-93-5p are presented as endogenous controls. B The schema of cisplatin-resistant analysis. ES-2 cells were transfected with 20 nM miRNA mimic for 24 h, and subsequently cells were treated with cisplatin containing medium (0, 1.25, 2.5, 5, 10, and 20 μM) for 48 h. C Expression of the chrXq27.3 miRNA cluster in transfected ES-2 cells measured using qPCR. D Cisplatin sensitivity of transfected ES-2 cells measured using the MTS assay. The viability of cells following transfection of each miRNA was compared with that of negative control (NC) mimic-transfected cells using the Kruskal–Wallis test at each cisplatin concentration. E Expression of the chrXq27.3 miRNA cluster in co-transfected ES-2 cells measured using qPCR. F Cisplatin sensitivity of co-transfected ES-2 cells measured using the MTS assay. The viability of cells following transfection of each miRNA was compared with that of NC mimic-transfected cells using the Kruskal–Wallis test at each cisplatin concentration. G Apoptosis assay of transfected cells treated with 5 µM cisplatin. The percentage of apoptotic cells was compared using Student’s t test. H Representative images and bar graph of clonogenic assay. The transfected cells were treated with 1 µM cisplatin for 8 days, and the number of colonies was compare using Student’s t test. Error bars represent standard errors of the mean. *p < 0.05, **p < 0.01, and ***p < 0.001.